Navigation Links
Cell Therapeutics Announces Data Safety and Monitoring Board Recommendation to Continue the GOG-0212 Phase 3 Clinical Trial of OPAXIOTM as Maintenance Therapy in Ovarian Cancer
Date:1/30/2013

SEATTLE, Jan. 31, 2013 /PRNewswire/ -- Cell Therapeutics, Inc. (CTI) (NASDAQ and MTA: CTIC) today announced that the Gynecologic Oncology Group (GOG) informed CTI that an independent Data Safety Monitoring Board (DSMB) recommended continuation of the GOG-0212 Phase 3 clinical trial of OPAXIOTM (paclitaxel poliglumex) as maintenance therapy in ovarian cancer with no changes following a planned interim survival analysis. CTI remains blinded to the interim analysis results. GOG-0212 is the largest maintenance study in this setting, having enrolled approximately 1,000 of the planned 1,100 patients. Enrollment is expected to be completed in 2013.

The trial is being conducted and managed by the GOG, which is one of the National Cancer Institute's (NCI) funded cooperative cancer research groups focused on the study of gynecologic malignancies.

"This is an important milestone for our OPAXIO clinical development program and potentially for women with advanced ovarian cancer," noted Steve Benner , M.D., Chief Medical Officer of CTI. "GOG-0212 seeks to address an important question on the role OPAXIO may play in maintenance therapy for ovarian cancer and potentially other solid tumors." 

The GOG-0212 study is a randomized, multicenter, open label Phase 3 trial of either monthly OPAXIO or Taxol® for up to 12 consecutive months compared to surveillance among women with advanced ovarian cancer who have no evidence of disease following first-line platinum-taxane based therapy. For purposes of registration, the primary endpoint of the study is overall survival of OPAXIO compared to surveillance. Secondary endpoints are progression-free survival, safety and quality of life. The statistical analysis plan calls for four interim analyses and one final analysis, each with boundaries for early closure for superior efficacy or for futility. The Company expects the next interi
'/>"/>

SOURCE Cell Therapeutics, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Cell Therapeutics, Inc. (CTI) to Report First Quarter Financial Results on April 20
2. Faruqi & Faruqi, LLP Encourages Investors Who Suffered Substantial Losses Investing in Chelsea Therapeutics International, Ltd. to Contact the Firm
3. Argos Therapeutics Secures $25 million Series D Financing to Commence Phase 3 ADAPT Study in Patients with Metastatic Renal Cell Carcinoma (mRCC) in Mid-2012
4. Novelos Therapeutics Announces Successful Completion of First Cohort In Lung Cancer Trial With I-124-CLR1404 (LIGHT) Cancer-Targeted PET Imaging Agent at UW Carbone Cancer Center
5. Zacks Industry Outlook Highlights: Eli Lilly, Forest Labs, ViroPharma, Novartis and United Therapeutics
6. Oxford BioTherapeutics Appoints Senior Industry Leader to Head its New Clinical Development Operations in Basel, Switzerland
7. Nektar Therapeutics Reports Financial Results for the First Quarter of 2012
8. Cara Therapeutics Licenses Novel Kappa Opioid Agonist, CR845, to Chong Kun Dang Pharmaceutical Corporation For South Korean Market
9. Frost & Sullivan: High Uptake of New Drug Therapies and Aging Population Expansion Keep the U.S. Retinal Therapeutics Market Buoyant
10. Zenobia Therapeutics, Inc. And BioBlocks, Inc. Announce Sale Of A Joint Fragment Library Ideal For Screening By All Popular Methods
11. New Forecast Shows Global Protein Therapeutics Market to Reach $143.4 Billion by 2015
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/22/2014)... 21, 2014 Abaxis, Inc. (NasdaqGS: ... analysis systems, today reported financial results for the second ... quarter overview: , Revenues of $53.9 million, up ... EPS of $0.24, up 33% over last year,s comparable ... from Abaxis Veterinary Reference Laboratories (AVRL) of $3.5 million, ...
(Date:10/22/2014)... , Oct. 22, 2014 Sanomedics International Holdings, ... report by Global Research & Data Services, demand for ... from 2014 through 2018, as demand for more accurate ... is the world,s largest market for thermometers, and ... thermometers is Sanomedics International Holdings, Inc. Sanomedics ...
(Date:10/22/2014)... REDWOOD CITY, Calif. , Oct. 22, 2014 ... ) today announced that results from the  IAP310 ... and Pain Medicine (RAPM), a peer-reviewed journal ... placebo-controlled, Phase 3 trial evaluating the safety and ... sufentanil sublingual tablet system (SSTS), for the treatment ...
Breaking Medicine Technology:Abaxis Reports Record Revenues for the Second Quarter of Fiscal 2015 2Abaxis Reports Record Revenues for the Second Quarter of Fiscal 2015 3Abaxis Reports Record Revenues for the Second Quarter of Fiscal 2015 4Abaxis Reports Record Revenues for the Second Quarter of Fiscal 2015 5Abaxis Reports Record Revenues for the Second Quarter of Fiscal 2015 6Abaxis Reports Record Revenues for the Second Quarter of Fiscal 2015 7Abaxis Reports Record Revenues for the Second Quarter of Fiscal 2015 8Abaxis Reports Record Revenues for the Second Quarter of Fiscal 2015 9Abaxis Reports Record Revenues for the Second Quarter of Fiscal 2015 10Abaxis Reports Record Revenues for the Second Quarter of Fiscal 2015 11Abaxis Reports Record Revenues for the Second Quarter of Fiscal 2015 12Abaxis Reports Record Revenues for the Second Quarter of Fiscal 2015 13Abaxis Reports Record Revenues for the Second Quarter of Fiscal 2015 14Sanomedics International Holdings Analyst Report: Taking Some Heat by BrokerBank Securities, Inc. 2AcelRx Announces Publication of Zalviso Phase 3 Abdominal Trial Results 2
... 17, 2011 Clontech Laboratories, Inc., a wholly-owned ... release of the Tet-Express Inducible Expression System ... expression technology yet. At the heart of this ... Clontech,s Tet-Off® Advanced transcriptional activator protein (the Tet-Express ...
... Echo Therapeutics, Inc. (OTC Bulletin Board: ... as a non-invasive, wireless, transdermal continuous glucose monitoring (tCGM) ... delivery, announced that development of the commercially ready Symphony ... that the system will be ready for demonstration in ...
Cached Medicine Technology:Announcement - Clontech Laboratories, Inc. Releases the Tet-Express™ Inducible Expression System 2Announcement - Clontech Laboratories, Inc. Releases the Tet-Express™ Inducible Expression System 3Echo Therapeutics Reports Symphony™ tCGM System Ahead of Schedule 2Echo Therapeutics Reports Symphony™ tCGM System Ahead of Schedule 3
(Date:10/22/2014)... Washington, D.C. (PRWEB) October 22, 2014 With ... November, a national survey by the American Institutes for Research ... they know how to use health insurance, but 42 percent ... review a plan’s details before signing up for coverage. , ... literacy, with only 20 percent able to calculate correctly how ...
(Date:10/22/2014)... 22, 2014 Losing Weight Your Body’s Way ... staring you in the face, it certainly can be difficult ... your body an extra favor by doing it the healthy ... diets. Instead, listen to your body, exercise regularly, and choose ... essential to losing weight; you need to exercise more and ...
(Date:10/22/2014)... WALTHAM, MA (PRWEB) October 22, 2014 ... developing new solutions for the treatment of bacterial infections, ... J. Sinskey has joined its board of directors. ... Microbiology and Engineering Systems at The Massachusetts Institute of ... the MIT faculty since 1968. Dr. Sinskey also holds ...
(Date:10/22/2014)... Tara Haelle HealthDay Reporter ... drinking among young adult men may lead to increased blood ... didn,t cause a similar rise in blood pressure for young ... fact, when young adult women drank lightly or moderately, their ... study found. "This finding parallels studies in older adult ...
(Date:10/22/2014)... HealthDay Reporter TUESDAY, Oct. 21, 2014 (HealthDay News) -- ... NBC News in Liberia has cleared the virus from ... Medical Center in Omaha, where he had been treated for the ... confirmed by the U.S. Centers for Disease Control and Prevention found ... NBC News reported Tuesday night. "Recovering from Ebola is ...
Breaking Medicine News(10 mins):Health News:Many Americans Fail to Ask Basic Questions Before Signing Up for Health Insurance, National Survey Finds 2Health News:Many Americans Fail to Ask Basic Questions Before Signing Up for Health Insurance, National Survey Finds 3Health News:Many Americans Fail to Ask Basic Questions Before Signing Up for Health Insurance, National Survey Finds 4Health News:ReductionGuruMD Presents Ways to Improve Your Weight Loss Results 2Health News:Akeso Biomedical Appoints Dr. Anthony J. Sinskey to Board of Directors 2Health News:Binge Drinking May Boost Blood Pressure in Young Men 2Health News:Binge Drinking May Boost Blood Pressure in Young Men 3Health News:Binge Drinking May Boost Blood Pressure in Young Men 4Health News:U.S. Cameraman Treated for Ebola 'Free' of the Virus 2Health News:U.S. Cameraman Treated for Ebola 'Free' of the Virus 3
... low oxygen, study suggests, , TUESDAY, Feb. 2 (HealthDay News) ... crucial to sudden infant death syndrome (SIDS), new research finds. ... of serotonin -- an important regulator of involuntary functions such ... died of other causes, the study found. This finding may ...
... Feb. 2 The National Committee for Quality Assurance (NCQA) ... of Ohio , the first health plan in Ohio ... , Medical Mutual,s wellness program is one of only 15 in ... , WHP is a comprehensive assessment of key areas of health ...
... over possible link between MMR vaccine, developmental disorder ... British medical journal The Lancet on Tuesday ... the measles, mumps and rubella vaccine to autism and ... Feb. 28, 1998, set off a worldwide furor, with ...
... (fictitious name) was born in Bangladesh yet raised in Montreal. At ... pretext of visiting her sick grandmother. The young woman was then ... resistance. The girl later wrote to her mother that she ... raped. After two months, her mother granted her return to Montreal. ...
... ... ... 22, 2010 -- Professional athletes, everyday athletes and even the occasional weekend warriors ... isn’t new technology – it’s been widely used and popular among European athletes ...
... parents over possible link between MMR vaccine, developmental disorder ... prestigious British medical journal The Lancet on ... linked the measles, mumps and rubella vaccine to autism ... Feb. 28, 1998, set off a worldwide furor, ...
Cached Medicine News:Health News:Serotonin May Be Key to Sudden Infant Deaths 2Health News:Serotonin May Be Key to Sudden Infant Deaths 3Health News:Medical Mutual is the First Ohio Health Plan to Receive NCQA Wellness & Health Accreditation 2Health News:Controversial Autism Study Retracted by Medical Journal 2Health News:Controversial Autism Study Retracted by Medical Journal 3Health News:Controversial Autism Study Retracted by Medical Journal 4Health News:From Quebec to France: forced marriages still exist 2Health News:Electrical Muscle Stimulation Proven to Enhance Muscle Development and Sports Performance 2Health News:Electrical Muscle Stimulation Proven to Enhance Muscle Development and Sports Performance 3Health News:Electrical Muscle Stimulation Proven to Enhance Muscle Development and Sports Performance 4Health News:Flawed Autism Study Retracted by Medical Journal 2Health News:Flawed Autism Study Retracted by Medical Journal 3
... SPECIFICATIONS Appearance/Form: White to buff-colored powder Activity: >=590g of ... (A&B): Passes tests Limit of Methanol: Specific Rotation ... pH (4%, H 2 O): 3.5 to 5.5 Loss ... C 1 : 25-50% C 2 + C ...
Gentamicin is a selection antibiotic used for selection of a Bac-to-Bac recombinant expression bacmid following transposition. Gentamicin is provided as a solution at a concentration of 50 mg/ml....
Gentamicin is an aminoglycosidic antibiotic that inhibits bacterial growth by inhibiting protein synthesis. Gentamicin is used for prevention and elimination of bacterial contaminants in cell culture...
1.0% Tryptone, 0.5% yeast extract, 0.5% Sodium Chloride, 0.6% agarose....
Medicine Products: